Remove tag investors
article thumbnail

Biogen’s Aduhelm rollout goes from bad to worse

pharmaphorum

Vounatsos also insisted that Aduhelm’s price tag has not been a factor discouraging treatment with the drug. Pushback from doctors in particular is causing anxiety for investors, as that may not be affected much if CMS opts to approve reimbursement, and shares in the company fell a little over 6% following the results announcement.

Insurance 118
article thumbnail

bluebird unveils $2.8m price for gene therapy Zynteglo on FDA approval

pharmaphorum

million price tag attached to the therapy when it was first made available in Europe, and is also well above the proposed $2.1 It slashed its workforce by 30% to reduce cash burn and extend its funded operations into the first half of 2023, so investors will be looking for signs of take-up of Zynteglo in the coming months.

FDA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Revolutionizing Medicine and Public Health: The Emergence of Big Data in Healthcare

Roots Analysis

Velocity: Big Data needs to be handled promptly as businesses generate data at an unprecedented speed, driven by the growing adoption of Internet of Things (IoT), and technologies, such as RFID tags, sensors, and smart meters are used to deal with the high velocity of data in real-time. It is loosely arranged into categories using meta tags.

article thumbnail

Ep. 008 – Vlad Mkrtumyan Podcast Transcript

Pharma Marketing Network

Don ( PMN): Yeah and that might be a concern for some folks out there that who’s websites are supported by advertising because you’re relying upon another third-party that can be adding load time to a site when you’re when you’re add tags are loading.

article thumbnail

STAT+: Pharmalittle: Bluebird claims big insurer will cover its sickle cell therapy; House Republicans threaten to subpoena FDA commish

STAT

… Bluebird Bio claimed a large insurer has agreed to cover its newly approved sickle cell disease gene therapy, easing some investor worries about resistance from other payers over the high price of the treatment, Reuters says. But Bluebird’s $3.1